The necessity of epidermal growth factor (EGF) in the process of mouse embryo development and outgrowth in vitro was studied. Mouse 4-cell stage embryos were cultured up to spreading stage (outgrowth) in human tubal fluid (HTF) medium alone (control) or with 10 ng/ml EGF and 1:250 diluted monoclonal antibodies against EGF (study groups). Hatching and outgrowth were significantly increased up to 60.9 and 52.4% respectively, while in the control only 33.7 and 20.4% reached hatching and outgrowth respectively. Moreover monoclonal antibodies against EGF significantly inhibited embryo development (P < 0.01). Only 5.8% of the embryos reached the hatching stage and none of them reached the spreading stage. Our results show that EGF is probably involved in the modulation of early embryonic growth and in the initiation of implantation.
Introduction
Despite the rapid development of assisted reproduction techniques in recent years, implantation rates after replacement of embryos into the uterine cavity remain low (Bongso et al., 1991) . Successful implantation of the embryo is dependent on the synchrony between the development of the embryo itself and the uterus (Edwards, 1995) . Although the details of the mechanisms that are involved in the regulation of embryo implantation are incomplete, it is clear that several growth factors are involved in the process (Giudice et al., 1995) . In recent years, several studies have investigated the influence of specific growth factors on mammalian embryo development in vitro. Epidermal growth factor (EGF), fibroblastic growth factor (FGF) and insulin-like growth factor (IGF) have been reported to influence the growth rate of mouse embryos (Colver et al., 1991; Goldman et al., 1993) . The involvement of EGF in implantation has been shown by several investigators. EGF is secreted from the uterus and may serve as a signal involved in the initiation of the final step of implantation. EGF receptors encoded by the embryonic genome are first detectable on the cells of 4-to 8-cell mouse embryos (Nexo et al., 1980; HuetHudson et al., 1990) . There are conflicting data about the role and importance of EGF in the process of mouse embryo implantation. The purpose of this study is to clarify this issue by examining the necessity of EGF in the process of mouse embryo outgrowth in vitro.
Materials and methods

Embryo collection and culture
Virgin ICR female mice at 6 weeks of age (Technion Animal Lab, Haifa, Israel) were superovulated by i.p. injection of 5 IU pregnant mare's serum gonadotrophin (PMSG; Teva, Kfar Saba, Israel). After 48 h 5 IU of human chorionic gonadotrophin (HCG; Chorigon, Teva) was administered, the females were allowed to mate with a single 12-14 week old ICR male. The females were then killed by cervical dislocation. The oviduct was flushed at 72 h following HCG. For the purpose of this study only 4-cell embryos were collected. The embryos were pooled with a mouth-operated micropipette and washed with human tubal fluid medium (HTF medium; Irvine Scientific, California, USA). EGF (Sigma E1257, Tel Aviv, Israel) was prepared as a 10 mg/ml stock solution and stored in 50 µl aliquots at -20°C until use. The embryos were grown in HTF medium, containing 4% Substitute Serum (Irvine Scientific, California, USA) alone (control group), and with 10 ng/ml EGF or 1: 250 diluted anti-EGF monoclonal antibodies (Sigma E2635, Tel Aviv, Israel) (study groups). The embryos were randomly allocated to the experimental groups. Up to five embryos were grown in each well containing 1 ml medium. The medium was changed every 48 h, and the cultures maintained at 37°C in 5% CO 2 . The embryos were inspected every 24 h for progression of growth through morula blastocyst stage up to the spreading stage (outgrowth), which may represent the ability of early implantation (Hogan et al., 1986) . The ability of outgrowth in vitro was examined and compared between the groups by the appearance of the spreading stage.
Results
The effect of EGF and anti-EGF on blastocyst development
HTF medium supplemented with 4% substitute serum (SS) was used in the control group. The same medium containing 10 ng/ml EGF or 1:250 diluted anti-EGF antibodies was used in the study groups. Table I presents the degree of embryo development to morula and blastocyst stage. Seventy eight and 74 out of 83 4-cell embryos (93.9 and 89.1%) developed to the morula and blastocyst stage respectively in the control group. Similar results were obtained in the presence of 10 ng/ ml EGF, 78 and 77 out of 82 4-cell embryos (95.1 and 93.9%) developed to the morula and blastocyst stage respectively, while in the presence of 1:250 diluted monoclonal anti-EGF antibodies 71 and 68 out of 85 4-cell embryos (83.5 and 80%) developed to the morula and blastocyst stage respectively. No significant differences were observed between the three groups. 
The effect of EGF and anti-EGF on implantation in vitro
Discussion
Embryos prepare themselves for implantation during their cleavage stages. Successive cleavages must produce a sufficient number of cells by the time the blastocyst is formed to permit the full formation of inner cell mass (ICM) and trophectoderm. An insufficient number of cells can jeopardize both the differentiation and the viability of the embryo (Edwards, 1995) . In our previous study we have shown that EGF caused significant morphological changes as reflected in the trophectoderm and ICM at the early spreading stage (Goldman et al., 1993) . In the present study we have demonstrated that EGF significantly increased the outgrowth in vitro as reflected by the number of embryos that reached the spreading stage. More interestingly, in the presence of anti-EGF none of the embryos reached spreading stage. Taga (1992) reported that anti-EGF antibodies exerted an inhibitory effect on DNA synthesis in a teratocarcinoma cell line, which shares biochemical characteristics with the embryo beyond the blastocyst stage. This cell line produces and secretes EGF. Therefore, the inhibitory effect of the antibodies may indicate an autocrine/paracrine mechanism of EGF action. Dardik et al. (1991) reported that adding neutralizing antibodies to EGF inhibits the EGF stimulatory effect. Brice et al. (1993) used anti-EGF receptor antibodies. In his study cavitation was significantly accelerated by the presence of antibodies, suggesting that antibody receptor binding mimics natural ligand-receptor binding and induces the signal transduction cascade. Since there was no addition of EGF to the medium, we may assume that the only source for EGF is the embryo itself. It is now accepted that the early embryo produces a number of growth factors and receptors, including EGF and EGF receptor (Schultz et al., 1993) . EGF receptor mRNA of maternal origin are present in zygote and 2-cell mouse embryos (Paria et al., 1993) , and EGF receptors encoded by the embryonic genome are first detectable on the cells of 4-to 8-cell mouse embryos (Giudice et al., 1995) . In this study, we found a significant difference between the three media. In the presence of EGF hatching and spreading stages were significantly increased, while monoclonal antibodies against EGF decreased hatching stage and moreover prevented outgrowth of mouse blastocysts (P Ͻ 0.01; Table II) . Our results are in agreement with others. O'Neill (1997) reported that EGF had no effect on embryo development up to the blastocyst stage. Others (Dardik et al., 1991; Taga, 1992; Brice et al., 1993) also reported that EGF significantly increased blastocyst and trophoblast outgrowth. From our results we may postulate that EGF is produced and secreted by the blastocyst. Thus, the antibodies in the culture medium could be binding to EGF, and be preventing the autocrine modulation of EGF by preventing the ligand-receptor binding. As a result EGF modulation of the signal transduction pathway also may be inhibited. It is tempting to assume that autocrine/paracrine mechanism of EGF action may be a key regulator of embryo outgrowth. Our data seem to suggest that EGF is important for normal development and implantation capacity of the embryos. Receptors for EGF have been identified in the pre-implanting embryos at the morula stage (Adamson et al., 1984) . It has been shown that the effect of EGF on morula-stage embryos appears to be localized to cells that are destined to form the trophectoderm cells, suggesting that EGF is important for normal differentiation (Wood et al., 1989) . EGF has also been reported to stimulate protein synthesis during the morulablastocyst transition and in post-implantation mouse embryonic tissue (Caro et al., 1987) . Our results show that anti-EGF prevents blastocyst outgrowth in vitro, by inhibiting the spreading stage. This observation may indicate auto regulation of EGF by the embryo. Several studies have shown that EGF is secreted from the uterus (Adamson et al., 1984; HuetHadson et al., 1990; Giudice et al., 1994) . The early embryo produces several growth factors and growth factor receptors. In addition, the oviduct and uterine endometrium also synthesize growth factors such as EGF. Preimplantation embryos in vivo are in a growth factor-rich milieu compared to conventional growth media used in vitro for human fertilization to treat infertility. We may assume that the absence of EGF in the growth media contributes to suboptimal conditions for normal embryo implantation. Harvey et al. (1995) reported that mouse blastocysts that are without EGF receptors exhibit altered adhesive properties and die shortly after initiation of implanta-tion. Moreover it was suggested by Birdsall et al. (1996) that EGF may have a role in the feto-maternal interface throughout pregnancy. Since we know that, theoretically, antibodies can penetrate through the cell membrane, based on the studies of Birdsall et al. (1996) and Sandberg et al. (1997) , we may also assume that anti-EGF antibodies can prevent gene transcription activated by EGF, and as a result interfere with embryo differentiation and implantation. The effect of EGF on embryonic development is complex. The timing and concentration of EGF secretion from the uterus near the embryo might have an important effect on the implantation process. Modulation by EGF probably involves a delicate balance between stimulatory and inhibitory effects on embryo development. Anti-EGF inhibits hatching and spreading possibly by neutralizing endogenic EGF activity which serves as an autocrine and paracrine factor.
Moreover this study provides an important clue for the necessity of EGF in the initiation of outgrowth. Further experiments are needed to provide a full understanding of this modulatory process.
